期刊
FUTURE ONCOLOGY
卷 11, 期 5, 页码 719-733出版社
FUTURE MEDICINE LTD
DOI: 10.2217/FON.14.272
关键词
JAK inhibitor; myelofibrosis; myeloproliferative neoplasm; polycythemia vera; primary myelofibrosis; ruxolitinib; splenomegaly
类别
资金
- Incyte
- AstraZeneca
- Lilly Oncology
- Geron
- NS Pharma
- Bristol-Myers Squibb
- Novartis
- Celgene
- Gilead
- Seattle Genetics
- Promedior
- Cell Therapeutics
- Incyte Corporation
- NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER
The JAK1 and JAK2 inhibitor ruxolitinib has approved indications in myelofibrosis, a BCR-AB1-negative myeloproliferative neoplasm associated with progressive bone marrow fibrosis and shortened survival. In Phase III clinical studies, ruxolitinib provided rapid and durable improvement of myelofibrosis-related splenomegaly and symptoms irrespective of mutation status, and was associated with a survival advantage compared with placebo or best available therapy. Because of dose-dependent cytopenias, blood count monitoring and dose titration are important to optimize therapy. Specific precautions apply to the treatment of patients with or at risk of serious infections. Discontinuation of ruxolitinib generally leads to symptom return within 1 week. Ruxolitinib also is approved for treatment of patients with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据